Thermo Fisher Scientific (TMO) Net Income towards Common Stockholders (2009 - 2026)

Thermo Fisher Scientific has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $1.7 billion for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 9.95% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 billion (up 6.12% YoY) and the FY2025 annual result came in at $6.8 billion, up 6.61% from the prior year.
• Net Income towards Common Stockholders fell to $1.7 billion in Q1 2026, from $2.0 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $2.2 billion in Q2 2022 and troughed at $1.3 billion in Q2 2023.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2023 frame the typical range for Net Income towards Common Stockholders.
• Biggest YoY gain for Net Income towards Common Stockholders was 14.72% in 2023; the steepest drop was 41.81% in 2023.
• Tracing TMO's Net Income towards Common Stockholders over 5 years: stood at $1.6 billion in 2022, then rose by 3.43% to $1.6 billion in 2023, then grew by 12.27% to $1.8 billion in 2024, then gained by 8.91% to $2.0 billion in 2025, then retreated by 16.86% to $1.7 billion in 2026.
• Business Quant data shows TMO's Net Income towards Common Stockholders at $1.7 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.6 billion in Q3 2025.